The incidence of chronic kidney disease (CKD) is increasing worldwide; however, the association between CKD and anemia and hyperuricemia has yet to be clarified. In addition, whether anemia and hyperuricemia only influence renal damage in combination with other comorbidities or whether they are direct causative factors is also controversial. Therefore, the aim of this longitudinal study was to investigate these issues in a large Taiwanese cohort. We enrolled 26,631 participants from the Taiwan Biobank (TWB) after excluding those with CKD at the baseline, all of whom had follow-up data for a median of 4 years. In this study, CKD was defined as an estimated glomerular filtration rate < 60 mL/min/1.73 m2, incident new-onset CKD was defined as the development of CKD during follow-up, anemia was defined as a hemoglobin level <13 mg/dL in males and <12 mg/dL in females, and hyperuricemia was defined as a serum uric acid (UA) level >7 mg/dL in males and >6 mg/dL in females. The participants were divided into four groups according to whether or not they had anemia and hyperuricemia. Multivariable analysis showed that low hemoglobin (per 1 g/dL; odds ratio [OR], 0.760; p < 0.001) and high serum UA (per 1 mg/dL; OR, 1.444; p < 0.001) in model 1 and anemia (OR, 2.367; p < 0.001) and hyperuricemia (OR, 2.516; p < 0.001) in model 2 were significantly associated with new-onset CKD. Furthermore, compared to the group without anemia or hyperuricemia, the groups with anemia without hyperuricemia (OR, 2.502; p < 0.001), without anemia with hyperuricemia (OR, 2.559; p < 0.001), and with anemia and hyperuricemia (OR, 5.505; p < 0.001) were significantly associated with new-onset CKD. There was a significant interaction between hemoglobin and serum UA and new-onset CKD (p < 0.001). In conclusion, we found that anemia and hyperuricemia were associated with new-onset CKD, respectively, and also had a synergetic effect on new-onset CKD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859151 | PMC |
| http://dx.doi.org/10.3390/ijerph20021421 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Glycogen Storage Disease Type Ia: A Retrospective Claims Analysis of Complications, Resource Utilization, and Cost of Care.
J Health Econ Outcomes Res
January 2025
Ultragenyx Pharmaceutical Inc., Novato, CA, USA.
Glycogen storage disease type Ia (GSDIa) is a rare inherited disorder resulting in potentially life-threatening hypoglycemia, metabolic abnormalities, and complications often requiring hospitalization. This retrospective database analysis assessed the complications, resource utilization, and costs in a large cohort of patients with GSDIa. We conducted a retrospective cohort study of GSDIa patients and matched non-GSDIa comparators utilizing the PharMetrics® Plus database.
View Article and Find Full Text PDFCase Report: A potentially pathogenic new variant of the gene found in a family experiencing autosomal dominant tubulointerstitial kidney disease.
Front Pediatr
December 2024
Department of Internal Medicine, North China University of Science and Technology, Tangshan, China.
Background: Autosomal dominant tubulointerstitial kidney disease (ADTKD) caused by -causing pathogenic variants (ADTKD-) is a rare group of heritable diseases. ADTKD- often manifests in childhood with symptoms such as mild hypotension, chronic kidney disease, hyperkalemia, anemia, and acidosis. The diagnosis of ADTKD- remains challenging.
View Article and Find Full Text PDFArticle Synopsis
- The study compares the effectiveness and complications of two bariatric surgeries: single anastomotic duodeno-ileal bypass with sleeve gastrectomy (SADI-S) and sleeve gastrectomy (SG) in treating obesity and metabolic syndrome.
- After analyzing data from 186 patients, the results indicated that SADI-S resulted in significantly better weight loss and higher remission rates for metabolic syndrome, but also presented more postoperative issues like bone mineral density loss and anemia compared to SG.
- The research suggests that while SADI-S may be more effective for weight and metabolic factors, SG could be better for patients concerned about bone health or nutritional deficiencies, highlighting the need for improved postoperative care.
Risky Remedy: Rasburicase-Induced Methemoglobinemia in Tumor Lysis Syndrome Complicated by G6PD Deficiency.
Cureus
November 2024
Hematology and Medical Oncology, University of Kentucky College of Medicine, Lexington, USA.
Tumor lysis syndrome (TLS) is a critical oncologic emergency characterized by metabolic disturbances resulting from rapid cancer cell lysis. Rasburicase, a recombinant urate oxidase, is the primary treatment for hyperuricemia in TLS but poses a risk for methemoglobinemia in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. We present the case of a 59-year-old male with diffuse large B-cell lymphoma (DLBCL) who developed spontaneous TLS.
View Article and Find Full Text PDFHemolytic Anemia Secondary to Rasburicase Treatment in the Setting of Glucose-6-Phosphate-Dehydrogenase Deficiency: A Case Report.
Cureus
October 2024
Hematology and Medical Oncology, Northwell Health, New Hyde Park, USA.
Rasburicase is a recombinant form of urate oxidase, a medication used to treat hyperuricemia by metabolizing uric acid into an inactive and more soluble metabolite, allantoin. An oxidizing agent, hydrogen peroxide, is produced during the conversion of uric acid to allantoin. We present here a case of hemolytic anemia secondary to rasburicase treatment which was later confirmed to have glucose-6-phosphate dehydrogenase deficiency (G6PDD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!